Medtech Archives - Page 2 of 115 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

INBRAIN Neuroelectronics Names Scott Huennekens Chairman of the Board

December 9, 2025

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

December 15, 2025

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics, Expanding Rare Disease Portfolio

December 8, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Medtech

Insulet Expands Omnipod U.S. Recycling Program Nationwide

Vektor Medical receives FDA 510(k) clearance expanding vMap’s non-invasive cardiac mapping capabilities

Owlet Launches TGA-Approved Dream Sock in Australia and New Zealand, Expanding Global Reach of Pediatric Health Monitoring

Valvosoft, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis, Receives CE Marking

Aptyx Expands With New Precision Extrusion Center of Excellence in Boston Medtech Corridor

Most Read

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

INBRAIN Neuroelectronics Names Scott Huennekens Chairman of the Board

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics, Expanding Rare Disease Portfolio

POPULAR CATEGORY

ABOUT US

FOLLOW US